Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 6Terminated 2Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 21Myelodysplastic Syndromes 7Leukemia 7Leukemia, Myelomonocytic, Chronic 5Recurrence 4Melanoma 4Congenital Abnormalities 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Myeloproliferative Disorders 3Neoplasms 2Neoplasm Metastasis 2Leukemia, Myelomonocytic, Acute 2Leukemia, Monocytic, Acute 2Leukemia, Megakaryoblastic, Acute 2Leukemia, Erythroblastic, Acute 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Blast Crisis 2Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thrombocythemia, Essential 1Primary Myelofibrosis 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Polycythemia Vera 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive 1Mesothelioma, Malignant 1

Interventions

Cyclophosphamide 10fludarabine phosphate 9Peripheral Blood Stem Cell Transplantation 8Busulfan 8Antilymphocyte Serum 8Mycophenolic Acid 7Whole-Body Irradiation 6Tacrolimus 6Methylprednisolone 6Methotrexate 6Cyclosporine 6Radiotherapy 5Filgrastim 5Cord Blood Stem Cell Transplantation 5Sirolimus 4Rituximab 4Flow Cytometry 4Cytarabine 4Thiotepa 3Melphalan 3Imatinib Mesylate 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Dasatinib 3venetoclax 2ponatinib 2aldesleukin 2Tretinoin 2Therapeutics 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Blast Crisis × Decitabine × Clear all
NCT05524857 2024-04-23

Combination of Fedratinib and Decitabine for Myeloproliferative Neoplasms (MPN)- Accelerated Phase (AP)/Blast Phase (BP)

Columbia University

Phase 1 Terminated
2 enrolled
Myeloid

Blast Crisis, Myeloproliferative Disorders

NCT01498445 2020-10-22

An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357)

M.D. Anderson Cancer Center

Phase 1/2 Terminated
32 enrolled 16 charts
MyeloidOther hematologic neoplasm

Blast Crisis, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡